Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells
Latest Information Update: 03 Jan 2025
Price :
$35 *
At a glance
- Drugs Anakinra (Primary)
- Indications Cytokine release syndrome
- Focus Therapeutic Use
- Acronyms PACER
- 31 Dec 2024 Planned initiation date changed from 1 Dec 2024 to 15 Jan 2025.
- 28 Nov 2024 New trial record